CRDF Stock Overview

A clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. More details

CRDF fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Analysts in good agreement that stock price will rise by 147.7%

Risk Analysis

Earnings are forecast to decline by an average of 27.7% per year for the next 3 years

Makes less than USD$1m in revenue ($688K)

Highly volatile share price over the past 3 months compared to the US market

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Cardiff Oncology, Inc. Competitors

AVITA Medical

NasdaqCM:RCEL

US$338.9m

Sera Prognostics

NasdaqGM:SERA

US$268.5m

Silence Therapeutics

NasdaqGM:SLN

US$330.5m

aTyr Pharma

NasdaqCM:ATYR

US$287.1m

Price History & Performance

Summary of share price highs, lows and changes for Cardiff Oncology
Historical stock prices
Current Share Price	US$4.34
52 Week High	US$6.42
52 Week Low	US$1.41
Beta	1.91
1 Month Change	76.42%
3 Month Change	56.68%
1 Year Change	199.31%
3 Year Change	-30.11%
5 Year Change	247.20%
Change since IPO	-99.73%

Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning

Dec 12

Recent updates

Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning

Dec 12

Cardiff Oncology: Some Data Are In; Here's What You Should Know And Look For Next

Nov 07

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Aug 01

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Feb 22

Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment

Sep 14

Cardiff Oncology: Down But Not Out

Aug 22

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Jun 20

Cardiff Oncology: Upcoming Readouts And Several Green Lights

Jun 07

Cardiff Oncology: Risky Investment

May 19

Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance

Mar 01

We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Jan 28

Cardiff: The Pfizer Interest Is Interesting

Dec 15

Circling Back On Cardiff Oncology

Oct 12

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Aug 26

Cardiff Oncology: Current Slump Doesn't Look Right

Jun 14

Shareholder Returns

	CRDF	US Biotechs	US Market
7D	-3.3%	2.1%	2.8%
1Y	199.3%	-3.8%	24.5%

Return vs Industry: CRDF exceeded the US Biotechs industry which returned -3.8% over the past year.

Return vs Market: CRDF exceeded the US Market which returned 24.5% over the past year.

Price Volatility

Is CRDF's price volatile compared to industry and market?
CRDF volatility
CRDF Average Weekly Movement	23.4%
Biotechs Industry Average Movement	10.7%
Market Average Movement	6.3%
10% most volatile stocks in US Market	17.1%
10% least volatile stocks in US Market	3.1%

Stable Share Price: CRDF's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: CRDF's weekly volatility has increased from 18% to 23% over the past year.

About the Company

Founded	Employees	CEO	Website
1999	32	Mark Erlander	www.cardiffoncology.com

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers.

Cardiff Oncology, Inc. Fundamentals Summary

How do Cardiff Oncology's earnings and revenue compare to its market cap?
CRDF fundamental statistics
Market cap	US$200.44m
Earnings (TTM)	-US$43.00m
Revenue (TTM)	US$688.00k

322.6x

P/S Ratio

-5.2x

P/E Ratio

Is CRDF overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CRDF income statement (TTM)
Revenue	US$688.00k
Cost of Revenue	US$34.90m
Gross Profit	-US$34.21m
Other Expenses	US$8.79m
Earnings	-US$43.00m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.84
Gross Margin	-4,973.11%
Net Profit Margin	-6,250.73%
Debt/Equity Ratio	0%

How did CRDF perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/26 00:34
End of Day Share Price	2024/12/26 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cardiff Oncology, Inc. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Raghuram Selvaraju	Aegis Capital Corporation
Sung Ji Nam	Avondale Partners
Bryan Brokmeier	Cantor Fitzgerald & Co.

CRDF Stock Overview

Rewards

Risk Analysis

Cardiff Oncology, Inc. Competitors

NasdaqCM:RCEL

US$338.9m

NasdaqGM:SERA

US$268.5m

NasdaqGM:SLN

US$330.5m

NasdaqCM:ATYR

US$287.1m

Price History & Performance

Recent News & Updates

Price target increased by 9.0% to US$10.25

Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning

Cardiff Oncology, Inc. has filed a Follow-on Equity Offering in the amount of $40.000009 million.

New major risk - Share price stability

Cardiff Oncology, Inc. has filed a Follow-on Equity Offering in the amount of $40.000009 million.

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Recent updates

Price target increased by 9.0% to US$10.25

Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning

Cardiff Oncology, Inc. has filed a Follow-on Equity Offering in the amount of $40.000009 million.

New major risk - Share price stability

Cardiff Oncology, Inc. has filed a Follow-on Equity Offering in the amount of $40.000009 million.

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Cardiff Oncology: Some Data Are In; Here's What You Should Know And Look For Next

We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Cardiff Oncology, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Insufficient new directors

We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely

Consensus revenue estimates increase by 61%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Cardiff Oncology, Inc., Annual General Meeting, Jun 20, 2024

Cardiff Oncology Presents Novel Preclinical Data At Aacr Annual Meeting 2024 That Supports Ongoing First-Line Ras-Mutated Mcrc Clinical Study

Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

Consensus EPS estimates upgraded to US$0.97 loss

We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Cardiff Oncology, Inc. Announces First Patient Dosed in Randomized First-Line RAS-Mutated Metastatic Colorectal Cancer Trial (CRDF-004)

Price target increased by 13% to US$9.03

Cardiff Oncology, Inc. Provides Clinical Update on Phase 2 Randomized Second-Line ONSEMBLE Trial in Patients with RAS-Mutated mCRC

Cardiff Oncology, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Cardiff Oncology, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Cardiff Oncology, Inc. Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, Including Single-Agent Activity from Onvansertib Monotherapy

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 48%

Cardiff Oncology, Inc Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship

Price target decreased by 7.8% to US$7.68

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Consensus revenue estimates fall by 50%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 14%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Cardiff Oncology Appoints Fairooz Kabbinavar as Chief Medical Officer

Price target decreased to US$8.49

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$8.49

Independent Director recently bought US$257k worth of stock

Price target decreased to US$10.70

Consensus forecasts updated

Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment

Price target decreased to US$12.70

Cardiff Oncology, Inc. Announces Plans for A Randomized Trial in Metastatic Colorectal Cancer (mCRC), Durability of Responses in Ongoing Phase 1B/2 Trial in mCRC

Cardiff Oncology: Down But Not Out

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Cardiff Oncology, Inc.(NasdaqCM:CRDF) dropped from Russell 2000 Value Index

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Cardiff Oncology: Upcoming Readouts And Several Green Lights

Cardiff Oncology: Risky Investment

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind